Search results
Weight loss pills, a Ozempic's big fan, and Merck's skin cancer drug: Pharma news roundup
Quartz· 58 minutes agoIt may take a weight loss pill for Eli Lilly to finally meet demand for its popular anti-obesity...
Earnings call: Merck sees organic growth despite market challenges
Investing.com· 2 days agoMerck (NS: PROR ) & Co., Inc. (MRK) reported its first-quarter results for 2024, revealing a slight...
Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors
Zacks via Yahoo Finance· 20 hours agoMerck (MRK) reached a significant support level, and could be a good pick for investors from a...
The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E
Zacks via Yahoo Finance· 23 hours agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 4 days agoMerck announced Monday that it is pulling the plug on its phase 3 trial of an experimental...
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks· 3 days agoMerck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
Check Out What Whales Are Doing With MRK - Merck & Co (NYSE:MRK)
Benzinga· 15 hours agoLoading... Loading... Investors with a lot of money to spend have taken a bullish stance on Merck & Co MRK . And retail traders should know. We noticed this today when the ...
Merck KGaA Confirms Outlook After Drop in Sales, Earnings
The Wall Street Journal· 2 days agoMerck KGaA confirmed and detailed its guidance for 2024 after it reported lower sales and earnings...
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Zacks via Yahoo Finance· 20 hours agoHere we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK),...
Is Johnson & Johnson Stock A Better Pick Over Merck?
Forbes· 3 days agoAlthough Merck trades at a higher valuation of 5.5x trailing revenues, compared to 4.2x for J&J, we think that this valuation gap will likely narrow over...